Breaking Finance News

Zacks Investment Research announced Teligent Inc (NASDAQ:TLGT), boosting its stock price target to $8.75 today

In a report released on 10/12/2016 Zacks Investment Research upped the price target of Teligent Inc (NASDAQ:TLGT) to $8.75 reporting a potential upside of 0.15%.

Having a price of $7.60, Teligent Inc (NASDAQ:TLGT) traded -2.71% lower on the day. The last closing price is up 10.08% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $7.69 and a 200-day moving average of $6.86. 40,707 shares of the stock traded hands, down from an average trading volume of 239,063

See Chart Below

Teligent Inc (NASDAQ:TLGT)

Teligent Inc has a 52 week low of $4.46 and a 52 week high of $9.18 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 4 brokers have issued a research note on the company. The average stock price target is $9.50 with 0 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 3 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Teligent Inc (NASDAQ:TLGT)

Teligent, Inc., formerly IGI Laboratories, Inc., is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It has two platforms: developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. Its pipeline includes over 30 Abbreviated New Drug Applications filed with the United States Food and Drug Administration for additional pharmaceutical products. It holds additional over 40 product candidates at various stages of its development pipeline, 10 of which are on stability testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.